

Angina Pectoris Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/A2086A499A00EN.html>

Date: January 2025

Pages: 137

Price: US\$ 4,850.00 (Single User License)

ID: A2086A499A00EN

Abstracts

The Global Angina Pectoris Drugs Market was valued at USD 12.3 billion in 2024 and is expected to grow at a steady rate of 4.1% CAGR between 2025 and 2034. This growth is largely driven by the increasing prevalence of cardiovascular diseases, significant advancements in therapeutic treatments, and a rapidly aging population. The rise in lifestyle-related health risks—such as poor diets, lack of physical activity, smoking, stress, and obesity—has contributed to a higher incidence of cardiovascular conditions, including angina. As the prevalence of heart disease continues to rise, the demand for effective treatment options is also expanding. The healthcare industry is responding with innovations aimed at improving the quality of life for patients dealing with angina. Additionally, factors such as rising healthcare awareness, improved healthcare infrastructure, and increasing accessibility to medication are further fueling the growth of this market.

The market is categorized by type, with stable angina leading the segment, accounting for a 51.3% share in 2024. This form of angina is the most common and is characterized by chest pain that is predictable and often triggered by physical exertion or emotional stress. Given its prevalence, stable angina has a significant impact on the market, especially as it is commonly found in patients with coronary artery disease. The availability of well-established treatment options—such as nitrates, beta-blockers, and calcium channel blockers—ensures efficient management of the condition, encouraging their widespread use among patients and healthcare professionals alike.

In terms of administration route, the angina pectoris drug market is divided into oral, injectable, and topical formulations. Oral medications take the lead in terms of market share and are projected to grow at a 4% CAGR throughout the forecast period. Oral

drugs, such as beta-blockers, nitrates, and calcium channel blockers, are commonly preferred due to their convenience and affordability. They are often the first choice for treating angina, as they can be easily administered without the need for frequent visits to healthcare facilities. These treatments offer lower manufacturing and distribution costs, making them an attractive option for both patients and providers. Given that angina pectoris requires long-term treatment, oral medications are ideal for daily use and can significantly enhance patient compliance.

The U.S. angina pectoris drug market, valued at USD 4.6 billion in 2024, plays a critical role in driving the overall market growth. The country's increasing prevalence of angina, combined with a demand for more effective therapies, has spurred market expansion. Moreover, the U.S. continues to be a leader in medical research and innovation, with ongoing developments in angina treatments, including advanced combination therapies and enhanced beta blockers, further accelerating market growth. This consistent advancement in drug development, coupled with the country's robust healthcare infrastructure, positions the U.S. as a significant contributor to the future success of the global market.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definition
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Rising prevalence of cardiovascular diseases
 - 3.2.1.2 Advancements in drug development
 - 3.2.1.3 Increasing lifestyle-related risk factors
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 Side effects associated with the drugs
 - 3.2.2.2 Growing adoption of minimally invasive surgeries
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY TYPE, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Stable angina
- 5.3 Unstable angina
- 5.4 Microvascular angina
- 5.5 Prinzmetal angina

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Beta blockers
- 6.3 Nitrates
- 6.4 Anti-platelets
- 6.5 Calcium channel blockers
- 6.6 Anticoagulants
- 6.7 ACE inhibitors
- 6.8 Other drug classes

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Oral
- 7.3 Injectable
- 7.4 Topical

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 (\$ MN)

- 8.1 Key trends
- 8.2 Hospital pharmacies

8.3 Retail pharmacies

8.4 Online pharmacies

CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Italy

9.3.5 Spain

9.3.6 Netherlands

9.4 Asia Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

CHAPTER 10 COMPANY PROFILES

10.1 AdvaCare Pharma

10.2 Amgen

10.3 AstraZeneca

10.4 Bayer

10.5 Boehringer Ingelheim International

- 10.6 Eli Lilly and Company
- 10.7 Gilead Sciences
- 10.8 GlaxoSmithKline
- 10.9 Merck
- 10.10 Novartis
- 10.11 Otsuka Pharmaceutical
- 10.12 Pfizer
- 10.13 Sanofi

I would like to order

Product name: Angina Pectoris Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/A2086A499A00EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A2086A499A00EN.html>